{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37"}]}],"title":"1 Positive Titer"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"Antibodies Detected"}],"denoms":[{"counts":[{"groupId":"OG000","value":"301"}],"units":"Participants"}],"description":"A participant was considered to have an anti-Necitumumab antibody response if anti-drug antibodies (ADA) were confirmed positive. Treatment emergent antibodies were defined as any anti-Necitumumab antibody titer equal to or greater than 4-fold the participant's baseline titer.","groups":[{"description":"Necitumumab + Pemetrexed + Cisplatin\n\nNecitumumab: 800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V. infusion\n\nPemetrexed: 500 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles\n\nCisplatin: 75 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles","id":"OG000","title":"Necitumumab + Pemextrexed + Cisplatin"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received at least one dose of necitumumab and had evaluable antibody data.","reportingStatus":"POSTED","timeFrame":"Baseline to Study Completion (Up to 31.6 Months)","title":"Number of Participants With Serum Anti-Necitumumab Antibody Assessment (Immunogenicity)","type":"SECONDARY","unitOfMeasure":"participants"}